nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—CYP1A2—Carmustine—lymphatic system cancer	0.151	0.234	CbGbCtD
Etoricoxib—CYP2E1—Mitoxantrone—lymphatic system cancer	0.123	0.19	CbGbCtD
Etoricoxib—CYP2C19—Teniposide—lymphatic system cancer	0.11	0.17	CbGbCtD
Etoricoxib—CYP2C9—Teniposide—lymphatic system cancer	0.0915	0.142	CbGbCtD
Etoricoxib—CYP3A4—Cytarabine—lymphatic system cancer	0.054	0.0837	CbGbCtD
Etoricoxib—CYP3A4—Teniposide—lymphatic system cancer	0.0532	0.0824	CbGbCtD
Etoricoxib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0372	0.0576	CbGbCtD
Etoricoxib—CYP3A4—Vincristine—lymphatic system cancer	0.0256	0.0397	CbGbCtD
Etoricoxib—Visual impairment—Carmustine—lymphatic system cancer	0.000632	0.00178	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000629	0.00177	CcSEcCtD
Etoricoxib—Fatigue—Fludarabine—lymphatic system cancer	0.000628	0.00177	CcSEcCtD
Etoricoxib—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000623	0.00176	CcSEcCtD
Etoricoxib—Hallucination—Vincristine—lymphatic system cancer	0.000623	0.00176	CcSEcCtD
Etoricoxib—Pain—Fludarabine—lymphatic system cancer	0.000623	0.00176	CcSEcCtD
Etoricoxib—Constipation—Fludarabine—lymphatic system cancer	0.000623	0.00176	CcSEcCtD
Etoricoxib—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000618	0.00174	CcSEcCtD
Etoricoxib—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.000616	0.00174	CcSEcCtD
Etoricoxib—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000615	0.00174	CcSEcCtD
Etoricoxib—Urethral disorder—Vincristine—lymphatic system cancer	0.000614	0.00173	CcSEcCtD
Etoricoxib—Eye disorder—Carmustine—lymphatic system cancer	0.000613	0.00173	CcSEcCtD
Etoricoxib—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000613	0.00173	CcSEcCtD
Etoricoxib—Hypersensitivity—Teniposide—lymphatic system cancer	0.00061	0.00172	CcSEcCtD
Etoricoxib—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00061	0.00172	CcSEcCtD
Etoricoxib—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00061	0.00172	CcSEcCtD
Etoricoxib—Flushing—Carmustine—lymphatic system cancer	0.000609	0.00172	CcSEcCtD
Etoricoxib—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000605	0.00171	CcSEcCtD
Etoricoxib—Anaemia—Bleomycin—lymphatic system cancer	0.000605	0.00171	CcSEcCtD
Etoricoxib—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0006	0.00169	CcSEcCtD
Etoricoxib—Asthenia—Teniposide—lymphatic system cancer	0.000594	0.00168	CcSEcCtD
Etoricoxib—Melaena—Methotrexate—lymphatic system cancer	0.000591	0.00167	CcSEcCtD
Etoricoxib—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000591	0.00167	CcSEcCtD
Etoricoxib—Pruritus—Teniposide—lymphatic system cancer	0.000586	0.00165	CcSEcCtD
Etoricoxib—Arrhythmia—Carmustine—lymphatic system cancer	0.000586	0.00165	CcSEcCtD
Etoricoxib—Cystitis—Methotrexate—lymphatic system cancer	0.000584	0.00165	CcSEcCtD
Etoricoxib—Cardiac disorder—Vincristine—lymphatic system cancer	0.000581	0.00164	CcSEcCtD
Etoricoxib—Alopecia—Carmustine—lymphatic system cancer	0.00058	0.00164	CcSEcCtD
Etoricoxib—Mental disorder—Carmustine—lymphatic system cancer	0.000575	0.00162	CcSEcCtD
Etoricoxib—Vaginal infection—Methotrexate—lymphatic system cancer	0.000571	0.00161	CcSEcCtD
Etoricoxib—Malnutrition—Carmustine—lymphatic system cancer	0.000571	0.00161	CcSEcCtD
Etoricoxib—Erythema—Carmustine—lymphatic system cancer	0.000571	0.00161	CcSEcCtD
Etoricoxib—Cough—Bleomycin—lymphatic system cancer	0.000571	0.00161	CcSEcCtD
Etoricoxib—Angiopathy—Vincristine—lymphatic system cancer	0.000568	0.0016	CcSEcCtD
Etoricoxib—Diarrhoea—Teniposide—lymphatic system cancer	0.000567	0.0016	CcSEcCtD
Etoricoxib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000564	0.00159	CcSEcCtD
Etoricoxib—Chest pain—Bleomycin—lymphatic system cancer	0.000557	0.00157	CcSEcCtD
Etoricoxib—Alopecia—Vincristine—lymphatic system cancer	0.000553	0.00156	CcSEcCtD
Etoricoxib—Mental disorder—Vincristine—lymphatic system cancer	0.000549	0.00155	CcSEcCtD
Etoricoxib—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000547	0.00154	CcSEcCtD
Etoricoxib—Ecchymosis—Methotrexate—lymphatic system cancer	0.000547	0.00154	CcSEcCtD
Etoricoxib—Neoplasm—Methotrexate—lymphatic system cancer	0.000547	0.00154	CcSEcCtD
Etoricoxib—Bladder pain—Methotrexate—lymphatic system cancer	0.000547	0.00154	CcSEcCtD
Etoricoxib—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000545	0.00154	CcSEcCtD
Etoricoxib—Alopecia—Mitoxantrone—lymphatic system cancer	0.000539	0.00152	CcSEcCtD
Etoricoxib—Confusional state—Bleomycin—lymphatic system cancer	0.000538	0.00152	CcSEcCtD
Etoricoxib—Vision blurred—Carmustine—lymphatic system cancer	0.000538	0.00152	CcSEcCtD
Etoricoxib—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000536	0.00151	CcSEcCtD
Etoricoxib—Tremor—Carmustine—lymphatic system cancer	0.000535	0.00151	CcSEcCtD
Etoricoxib—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000534	0.00151	CcSEcCtD
Etoricoxib—Oedema—Bleomycin—lymphatic system cancer	0.000534	0.00151	CcSEcCtD
Etoricoxib—Erythema—Mitoxantrone—lymphatic system cancer	0.000531	0.0015	CcSEcCtD
Etoricoxib—Infection—Bleomycin—lymphatic system cancer	0.00053	0.0015	CcSEcCtD
Etoricoxib—Anaemia—Carmustine—lymphatic system cancer	0.000528	0.00149	CcSEcCtD
Etoricoxib—Vomiting—Teniposide—lymphatic system cancer	0.000527	0.00149	CcSEcCtD
Etoricoxib—Agitation—Carmustine—lymphatic system cancer	0.000525	0.00148	CcSEcCtD
Etoricoxib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000523	0.00147	CcSEcCtD
Etoricoxib—Asthenia—Fludarabine—lymphatic system cancer	0.000522	0.00147	CcSEcCtD
Etoricoxib—Rash—Teniposide—lymphatic system cancer	0.000522	0.00147	CcSEcCtD
Etoricoxib—Dermatitis—Teniposide—lymphatic system cancer	0.000522	0.00147	CcSEcCtD
Etoricoxib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00052	0.00147	CcSEcCtD
Etoricoxib—Headache—Teniposide—lymphatic system cancer	0.000519	0.00146	CcSEcCtD
Etoricoxib—Pruritus—Fludarabine—lymphatic system cancer	0.000515	0.00145	CcSEcCtD
Etoricoxib—Anorexia—Bleomycin—lymphatic system cancer	0.000509	0.00144	CcSEcCtD
Etoricoxib—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000505	0.00142	CcSEcCtD
Etoricoxib—Anaemia—Vincristine—lymphatic system cancer	0.000504	0.00142	CcSEcCtD
Etoricoxib—Agitation—Vincristine—lymphatic system cancer	0.000501	0.00141	CcSEcCtD
Etoricoxib—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0005	0.00141	CcSEcCtD
Etoricoxib—Diarrhoea—Fludarabine—lymphatic system cancer	0.000498	0.00141	CcSEcCtD
Etoricoxib—Hypertension—Carmustine—lymphatic system cancer	0.000493	0.00139	CcSEcCtD
Etoricoxib—Nausea—Teniposide—lymphatic system cancer	0.000492	0.00139	CcSEcCtD
Etoricoxib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000491	0.00138	CcSEcCtD
Etoricoxib—Hepatic failure—Methotrexate—lymphatic system cancer	0.000489	0.00138	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000486	0.00137	CcSEcCtD
Etoricoxib—Chest pain—Carmustine—lymphatic system cancer	0.000486	0.00137	CcSEcCtD
Etoricoxib—Anxiety—Carmustine—lymphatic system cancer	0.000484	0.00137	CcSEcCtD
Etoricoxib—Dyspnoea—Bleomycin—lymphatic system cancer	0.000476	0.00134	CcSEcCtD
Etoricoxib—Hypertension—Vincristine—lymphatic system cancer	0.000471	0.00133	CcSEcCtD
Etoricoxib—Confusional state—Carmustine—lymphatic system cancer	0.00047	0.00133	CcSEcCtD
Etoricoxib—Oedema—Carmustine—lymphatic system cancer	0.000466	0.00131	CcSEcCtD
Etoricoxib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000464	0.00131	CcSEcCtD
Etoricoxib—Visual disturbance—Methotrexate—lymphatic system cancer	0.000463	0.00131	CcSEcCtD
Etoricoxib—Cough—Mitoxantrone—lymphatic system cancer	0.000463	0.00131	CcSEcCtD
Etoricoxib—Infection—Carmustine—lymphatic system cancer	0.000463	0.00131	CcSEcCtD
Etoricoxib—Vomiting—Fludarabine—lymphatic system cancer	0.000463	0.00131	CcSEcCtD
Etoricoxib—Rash—Fludarabine—lymphatic system cancer	0.000459	0.0013	CcSEcCtD
Etoricoxib—Dermatitis—Fludarabine—lymphatic system cancer	0.000459	0.00129	CcSEcCtD
Etoricoxib—Hypertension—Mitoxantrone—lymphatic system cancer	0.000458	0.00129	CcSEcCtD
Etoricoxib—Pain—Bleomycin—lymphatic system cancer	0.000456	0.00129	CcSEcCtD
Etoricoxib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000456	0.00129	CcSEcCtD
Etoricoxib—Headache—Fludarabine—lymphatic system cancer	0.000456	0.00129	CcSEcCtD
Etoricoxib—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000454	0.00128	CcSEcCtD
Etoricoxib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000452	0.00127	CcSEcCtD
Etoricoxib—Chest pain—Mitoxantrone—lymphatic system cancer	0.000452	0.00127	CcSEcCtD
Etoricoxib—Anxiety—Mitoxantrone—lymphatic system cancer	0.00045	0.00127	CcSEcCtD
Etoricoxib—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000448	0.00126	CcSEcCtD
Etoricoxib—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000445	0.00126	CcSEcCtD
Etoricoxib—Oedema—Vincristine—lymphatic system cancer	0.000445	0.00126	CcSEcCtD
Etoricoxib—Anorexia—Carmustine—lymphatic system cancer	0.000444	0.00125	CcSEcCtD
Etoricoxib—Infection—Vincristine—lymphatic system cancer	0.000442	0.00125	CcSEcCtD
Etoricoxib—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00044	0.00124	CcSEcCtD
Etoricoxib—Confusional state—Mitoxantrone—lymphatic system cancer	0.000437	0.00123	CcSEcCtD
Etoricoxib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000436	0.00123	CcSEcCtD
Etoricoxib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000436	0.00123	CcSEcCtD
Etoricoxib—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000433	0.00122	CcSEcCtD
Etoricoxib—Oedema—Mitoxantrone—lymphatic system cancer	0.000433	0.00122	CcSEcCtD
Etoricoxib—Nausea—Fludarabine—lymphatic system cancer	0.000432	0.00122	CcSEcCtD
Etoricoxib—Infection—Mitoxantrone—lymphatic system cancer	0.00043	0.00121	CcSEcCtD
Etoricoxib—Shock—Mitoxantrone—lymphatic system cancer	0.000426	0.0012	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000425	0.0012	CcSEcCtD
Etoricoxib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000424	0.0012	CcSEcCtD
Etoricoxib—Urticaria—Bleomycin—lymphatic system cancer	0.000424	0.0012	CcSEcCtD
Etoricoxib—Anorexia—Vincristine—lymphatic system cancer	0.000424	0.0012	CcSEcCtD
Etoricoxib—Insomnia—Carmustine—lymphatic system cancer	0.000421	0.00119	CcSEcCtD
Etoricoxib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000421	0.00119	CcSEcCtD
Etoricoxib—Dyspnoea—Carmustine—lymphatic system cancer	0.000415	0.00117	CcSEcCtD
Etoricoxib—Somnolence—Carmustine—lymphatic system cancer	0.000414	0.00117	CcSEcCtD
Etoricoxib—Anorexia—Mitoxantrone—lymphatic system cancer	0.000413	0.00117	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000405	0.00114	CcSEcCtD
Etoricoxib—Decreased appetite—Carmustine—lymphatic system cancer	0.000405	0.00114	CcSEcCtD
Etoricoxib—Insomnia—Vincristine—lymphatic system cancer	0.000402	0.00114	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000402	0.00114	CcSEcCtD
Etoricoxib—Pain—Carmustine—lymphatic system cancer	0.000398	0.00112	CcSEcCtD
Etoricoxib—Constipation—Carmustine—lymphatic system cancer	0.000398	0.00112	CcSEcCtD
Etoricoxib—Breast disorder—Methotrexate—lymphatic system cancer	0.000397	0.00112	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000395	0.00112	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000395	0.00111	CcSEcCtD
Etoricoxib—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000393	0.00111	CcSEcCtD
Etoricoxib—Decreased appetite—Vincristine—lymphatic system cancer	0.000387	0.00109	CcSEcCtD
Etoricoxib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000386	0.00109	CcSEcCtD
Etoricoxib—Somnolence—Mitoxantrone—lymphatic system cancer	0.000385	0.00109	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000384	0.00108	CcSEcCtD
Etoricoxib—Feeling abnormal—Carmustine—lymphatic system cancer	0.000384	0.00108	CcSEcCtD
Etoricoxib—Fatigue—Vincristine—lymphatic system cancer	0.000383	0.00108	CcSEcCtD
Etoricoxib—Asthenia—Bleomycin—lymphatic system cancer	0.000383	0.00108	CcSEcCtD
Etoricoxib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000381	0.00108	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000381	0.00108	CcSEcCtD
Etoricoxib—Pain—Vincristine—lymphatic system cancer	0.00038	0.00107	CcSEcCtD
Etoricoxib—Constipation—Vincristine—lymphatic system cancer	0.00038	0.00107	CcSEcCtD
Etoricoxib—Pruritus—Bleomycin—lymphatic system cancer	0.000378	0.00107	CcSEcCtD
Etoricoxib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000377	0.00106	CcSEcCtD
Etoricoxib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000373	0.00105	CcSEcCtD
Etoricoxib—Pancreatitis—Methotrexate—lymphatic system cancer	0.000372	0.00105	CcSEcCtD
Etoricoxib—Pain—Mitoxantrone—lymphatic system cancer	0.00037	0.00105	CcSEcCtD
Etoricoxib—Constipation—Mitoxantrone—lymphatic system cancer	0.00037	0.00105	CcSEcCtD
Etoricoxib—Abdominal pain—Carmustine—lymphatic system cancer	0.000368	0.00104	CcSEcCtD
Etoricoxib—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000364	0.00103	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000364	0.00103	CcSEcCtD
Etoricoxib—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000357	0.00101	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000354	0.000999	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000353	0.000995	CcSEcCtD
Etoricoxib—Abdominal pain—Vincristine—lymphatic system cancer	0.000352	0.000992	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000346	0.000977	CcSEcCtD
Etoricoxib—Urticaria—Mitoxantrone—lymphatic system cancer	0.000344	0.000971	CcSEcCtD
Etoricoxib—Hypersensitivity—Carmustine—lymphatic system cancer	0.000343	0.000969	CcSEcCtD
Etoricoxib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000342	0.000966	CcSEcCtD
Etoricoxib—Pneumonia—Methotrexate—lymphatic system cancer	0.00034	0.00096	CcSEcCtD
Etoricoxib—Vomiting—Bleomycin—lymphatic system cancer	0.000339	0.000958	CcSEcCtD
Etoricoxib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000338	0.000955	CcSEcCtD
Etoricoxib—Infestation—Methotrexate—lymphatic system cancer	0.000338	0.000955	CcSEcCtD
Etoricoxib—Rash—Bleomycin—lymphatic system cancer	0.000337	0.00095	CcSEcCtD
Etoricoxib—Dermatitis—Bleomycin—lymphatic system cancer	0.000336	0.000949	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000336	0.000947	CcSEcCtD
Etoricoxib—Asthenia—Carmustine—lymphatic system cancer	0.000334	0.000943	CcSEcCtD
Etoricoxib—Renal failure—Methotrexate—lymphatic system cancer	0.000333	0.000939	CcSEcCtD
Etoricoxib—Stomatitis—Methotrexate—lymphatic system cancer	0.00033	0.000931	CcSEcCtD
Etoricoxib—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000329	0.000928	CcSEcCtD
Etoricoxib—Hypersensitivity—Vincristine—lymphatic system cancer	0.000328	0.000925	CcSEcCtD
Etoricoxib—Haematuria—Methotrexate—lymphatic system cancer	0.000323	0.00091	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00032	0.000903	CcSEcCtD
Etoricoxib—Epistaxis—Methotrexate—lymphatic system cancer	0.000319	0.000901	CcSEcCtD
Etoricoxib—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000319	0.0009	CcSEcCtD
Etoricoxib—Asthenia—Vincristine—lymphatic system cancer	0.000319	0.0009	CcSEcCtD
Etoricoxib—Diarrhoea—Carmustine—lymphatic system cancer	0.000319	0.0009	CcSEcCtD
Etoricoxib—Nausea—Bleomycin—lymphatic system cancer	0.000317	0.000895	CcSEcCtD
Etoricoxib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000311	0.000877	CcSEcCtD
Etoricoxib—Dizziness—Carmustine—lymphatic system cancer	0.000308	0.000869	CcSEcCtD
Etoricoxib—Haemoglobin—Methotrexate—lymphatic system cancer	0.000305	0.000861	CcSEcCtD
Etoricoxib—Diarrhoea—Vincristine—lymphatic system cancer	0.000304	0.000859	CcSEcCtD
Etoricoxib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000304	0.000857	CcSEcCtD
Etoricoxib—Hepatitis—Methotrexate—lymphatic system cancer	0.000304	0.000857	CcSEcCtD
Etoricoxib—Pharyngitis—Methotrexate—lymphatic system cancer	0.000302	0.000851	CcSEcCtD
Etoricoxib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.0003	0.000846	CcSEcCtD
Etoricoxib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000298	0.00084	CcSEcCtD
Etoricoxib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000296	0.000836	CcSEcCtD
Etoricoxib—Vomiting—Carmustine—lymphatic system cancer	0.000296	0.000836	CcSEcCtD
Etoricoxib—Dizziness—Vincristine—lymphatic system cancer	0.000294	0.00083	CcSEcCtD
Etoricoxib—Rash—Carmustine—lymphatic system cancer	0.000294	0.000829	CcSEcCtD
Etoricoxib—Dermatitis—Carmustine—lymphatic system cancer	0.000294	0.000828	CcSEcCtD
Etoricoxib—Visual impairment—Methotrexate—lymphatic system cancer	0.000293	0.000826	CcSEcCtD
Etoricoxib—Headache—Carmustine—lymphatic system cancer	0.000292	0.000824	CcSEcCtD
Etoricoxib—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000287	0.00081	CcSEcCtD
Etoricoxib—Eye disorder—Methotrexate—lymphatic system cancer	0.000284	0.000801	CcSEcCtD
Etoricoxib—Tinnitus—Methotrexate—lymphatic system cancer	0.000283	0.000799	CcSEcCtD
Etoricoxib—Vomiting—Vincristine—lymphatic system cancer	0.000283	0.000798	CcSEcCtD
Etoricoxib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000282	0.000795	CcSEcCtD
Etoricoxib—Rash—Vincristine—lymphatic system cancer	0.00028	0.000791	CcSEcCtD
Etoricoxib—Dermatitis—Vincristine—lymphatic system cancer	0.00028	0.000791	CcSEcCtD
Etoricoxib—Headache—Vincristine—lymphatic system cancer	0.000279	0.000786	CcSEcCtD
Etoricoxib—Nausea—Carmustine—lymphatic system cancer	0.000277	0.000781	CcSEcCtD
Etoricoxib—Angiopathy—Methotrexate—lymphatic system cancer	0.000276	0.000778	CcSEcCtD
Etoricoxib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000275	0.000777	CcSEcCtD
Etoricoxib—Immune system disorder—Methotrexate—lymphatic system cancer	0.000274	0.000774	CcSEcCtD
Etoricoxib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000274	0.000772	CcSEcCtD
Etoricoxib—Rash—Mitoxantrone—lymphatic system cancer	0.000273	0.000771	CcSEcCtD
Etoricoxib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000273	0.00077	CcSEcCtD
Etoricoxib—Headache—Mitoxantrone—lymphatic system cancer	0.000271	0.000766	CcSEcCtD
Etoricoxib—Alopecia—Methotrexate—lymphatic system cancer	0.000268	0.000757	CcSEcCtD
Etoricoxib—Mental disorder—Methotrexate—lymphatic system cancer	0.000266	0.000751	CcSEcCtD
Etoricoxib—Malnutrition—Methotrexate—lymphatic system cancer	0.000264	0.000746	CcSEcCtD
Etoricoxib—Erythema—Methotrexate—lymphatic system cancer	0.000264	0.000746	CcSEcCtD
Etoricoxib—Nausea—Vincristine—lymphatic system cancer	0.000264	0.000745	CcSEcCtD
Etoricoxib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000259	0.000731	CcSEcCtD
Etoricoxib—Nausea—Mitoxantrone—lymphatic system cancer	0.000257	0.000726	CcSEcCtD
Etoricoxib—Vision blurred—Methotrexate—lymphatic system cancer	0.000249	0.000703	CcSEcCtD
Etoricoxib—Anaemia—Methotrexate—lymphatic system cancer	0.000244	0.00069	CcSEcCtD
Etoricoxib—Cough—Methotrexate—lymphatic system cancer	0.000231	0.000651	CcSEcCtD
Etoricoxib—Arthralgia—Methotrexate—lymphatic system cancer	0.000225	0.000635	CcSEcCtD
Etoricoxib—Chest pain—Methotrexate—lymphatic system cancer	0.000225	0.000635	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000224	0.000631	CcSEcCtD
Etoricoxib—Confusional state—Methotrexate—lymphatic system cancer	0.000218	0.000614	CcSEcCtD
Etoricoxib—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000216	0.000609	CcSEcCtD
Etoricoxib—Infection—Methotrexate—lymphatic system cancer	0.000214	0.000605	CcSEcCtD
Etoricoxib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000212	0.000597	CcSEcCtD
Etoricoxib—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000211	0.000596	CcSEcCtD
Etoricoxib—Skin disorder—Methotrexate—lymphatic system cancer	0.00021	0.000592	CcSEcCtD
Etoricoxib—Anorexia—Methotrexate—lymphatic system cancer	0.000206	0.00058	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000197	0.000555	CcSEcCtD
Etoricoxib—Insomnia—Methotrexate—lymphatic system cancer	0.000195	0.000551	CcSEcCtD
Etoricoxib—Dyspnoea—Methotrexate—lymphatic system cancer	0.000192	0.000543	CcSEcCtD
Etoricoxib—Somnolence—Methotrexate—lymphatic system cancer	0.000192	0.000541	CcSEcCtD
Etoricoxib—Dyspepsia—Methotrexate—lymphatic system cancer	0.00019	0.000536	CcSEcCtD
Etoricoxib—Decreased appetite—Methotrexate—lymphatic system cancer	0.000188	0.000529	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000186	0.000526	CcSEcCtD
Etoricoxib—Fatigue—Methotrexate—lymphatic system cancer	0.000186	0.000525	CcSEcCtD
Etoricoxib—Pain—Methotrexate—lymphatic system cancer	0.000185	0.000521	CcSEcCtD
Etoricoxib—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000178	0.000502	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000176	0.000498	CcSEcCtD
Etoricoxib—Urticaria—Methotrexate—lymphatic system cancer	0.000171	0.000484	CcSEcCtD
Etoricoxib—Abdominal pain—Methotrexate—lymphatic system cancer	0.000171	0.000481	CcSEcCtD
Etoricoxib—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000159	0.000449	CcSEcCtD
Etoricoxib—Asthenia—Methotrexate—lymphatic system cancer	0.000155	0.000437	CcSEcCtD
Etoricoxib—Pruritus—Methotrexate—lymphatic system cancer	0.000153	0.000431	CcSEcCtD
Etoricoxib—Diarrhoea—Methotrexate—lymphatic system cancer	0.000148	0.000417	CcSEcCtD
Etoricoxib—Dizziness—Methotrexate—lymphatic system cancer	0.000143	0.000403	CcSEcCtD
Etoricoxib—Vomiting—Methotrexate—lymphatic system cancer	0.000137	0.000387	CcSEcCtD
Etoricoxib—Rash—Methotrexate—lymphatic system cancer	0.000136	0.000384	CcSEcCtD
Etoricoxib—Dermatitis—Methotrexate—lymphatic system cancer	0.000136	0.000384	CcSEcCtD
Etoricoxib—Headache—Methotrexate—lymphatic system cancer	0.000135	0.000381	CcSEcCtD
Etoricoxib—Nausea—Methotrexate—lymphatic system cancer	0.000128	0.000362	CcSEcCtD
